{
  "cik": 1776111,
  "cik_padded": "0001776111",
  "entityName": "MBX Biosciences, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-103121",
      "filed": "2026-03-12",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 1929000.0,
        "cash": 75289000.0,
        "eps_diluted": -2.38,
        "free_cash_flow": -81878000.0,
        "net_income": -86971000.0,
        "operating_cash_flow": -79949000.0,
        "operating_income": -98055000.0,
        "stockholders_equity": 369223000.0,
        "total_assets": 385144000.0,
        "total_liabilities": 15921000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.04312028232260721,
        "roa_avg2y": -0.2660969680837231,
        "roa_period_end": -0.22581424090729701,
        "roe_avg2y": -0.27756775948872203,
        "roe_period_end": -0.2355514147276849
      }
    },
    {
      "accn": "0001193125-26-103121",
      "filed": "2026-03-12",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 874000.0,
        "cash": 49351000.0,
        "eps_diluted": -5.82,
        "free_cash_flow": -55555000.0,
        "net_income": -61922000.0,
        "operating_cash_flow": -54681000.0,
        "operating_income": -68194000.0,
        "stockholders_equity": 257442000.0,
        "total_assets": 268535000.0,
        "total_liabilities": 11093000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.043089317205428794,
        "roa_avg2y": -0.35111634038813205,
        "roa_period_end": -0.23059191539277932,
        "roe_avg2y": -0.6695211218874004,
        "roe_period_end": -0.24052796358014622
      }
    },
    {
      "accn": "0001193125-26-103121",
      "filed": "2026-03-12",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 129000.0,
        "cash": 30523000.0,
        "eps_diluted": -31.96,
        "free_cash_flow": -32107000.0,
        "net_income": -32563000.0,
        "operating_cash_flow": -31978000.0,
        "operating_income": -35311000.0,
        "stockholders_equity": -72468000.0,
        "total_assets": 84180000.0,
        "total_liabilities": 4291000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.38682584937039677,
        "roe_avg2y": 0.565953785857673
      }
    },
    {
      "accn": "0000950170-25-039838",
      "filed": "2025-03-17",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -42605000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-103121",
    "filed": "2026-03-12",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001776111.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001776111.json"
  },
  "ticker": "MBX"
}